Anemia Research Today is a free monthly online journal that collates and summarizes the latest research about Anemia, including details on symptoms, diagnosis, diet, treatment, causes.

Volume 6 (2009), Issue 5 (May)

1. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.
   J Am Soc Nephrol, 20(5): 940-9. [Abstract] [Full-text]
2. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
   Cancer Chemother Pharmacol, 64(1): 177-81. [Abstract] [Full-text]
3. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
   Lancet, 373(9674): 1532-42. [Abstract] [Full-text]
4. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
   J Immunol, 182(10): 6394-400. [Abstract] [Full-text]
5. Dural venous thrombosis following splenectomy in a patient with hereditary spherocytosis.
   South Med J, 102(5): 542-5. [Abstract] [Full-text]
6. Religious/Spiritual coping in adolescents with sickle cell disease: a pilot study.
   J Pediatr Hematol Oncol, 31(5): 313-8. [Abstract] [Full-text]
7. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.
   J Pediatr Hematol Oncol, 31(5): 309-12. [Abstract] [Full-text]
8. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity.
   N Engl J Med, 360(19): 1971-80. [Abstract] [Full-text]
9. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.
   Blood, 113(19): 4763-70. [Abstract] [Full-text]
10. Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults.
    Transfusion, 49(5): 863-8. [Abstract] [Full-text]
11. Oxidised low-density lipoprotein and arterial function in beta-thalassemia major.
    Eur J Haematol, 82(6): 477-83. [Abstract] [Full-text]
12. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
    Eur J Haematol, 82(6): 454-7. [Abstract] [Full-text]
13. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Eur J Haematol, 82(6): 458-65. [Abstract] [Full-text]
14. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
    Transfusion, 49(5): 895-902. [Abstract] [Full-text]
15. Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria.
    Leukemia, 23(5): 886-91. [Abstract] [Full-text]
16. Growth status in children and adolescents with sickle cell disease.
    Pediatr Hematol Oncol, 26(4): 202-15. [Abstract] [Full-text]
17. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
    Pediatr Hematol Oncol, 26(4): 195-201. [Abstract] [Full-text]
18. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles.
    Pediatr Hematol Oncol, 26(4): 186-94. [Abstract] [Full-text]
19. Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin.
    Pediatr Blood Cancer, 53(1): 90-1. [Abstract] [Full-text]
20. 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer.
    Pediatr Blood Cancer, 53(1): 7-12. [Abstract] [Full-text]
21. The significance of bone marrow cell morphology and its correlation with cytogenetic features in the diagnosis of MDS-RA patients.
    Leuk Res, 33(8): 1029-38. [Abstract] [Full-text]
22. Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis.
    Crit Care Med, 37(6): 1906-12. [Abstract] [Full-text]
23. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
    J Immunol, 182(11): 7009-18. [Abstract] [Full-text]
24. Periconceptional iron and folate status is inadequate among married, nulliparous women in rural Bangladesh.
    J Nutr, 139(6): 1179-84. [Abstract] [Full-text]
25. Interleukin-23 receptor (IL-23R) gene polymorphisms in acquired aplastic anemia.
    Ann Hematol, 88(7): 653-7. [Abstract] [Full-text]
26. Aplastic anemia and concomitant autoimmune diseases.
    Ann Hematol, 88(7): 659-65. [Abstract] [Full-text]
27. Effect of soluble fiber pectin on growth and intestinal iron absorption in rats during recovery from iron deficiency anemia.
    Biol Trace Elem Res, 129(1): 221-8. [Abstract] [Full-text]
28. Phagocytosis, oxidative burst, and produced reactive species are affected by iron deficiency anemia and anemia of chronic diseases in elderly.
    Biol Trace Elem Res, 129(1): 116-25. [Abstract] [Full-text]
29. Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation.
    Am Heart J, 157(6): 1057-63. [Abstract] [Full-text]
30. A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.
    Ann Oncol, 20(6): 1105-12. [Abstract] [Full-text]
31. Quantitative risk assessment for verocytotoxigenic Escherichia coli in ground beef hamburgers in Argentina.
    Int J Food Microbiol, 132(2): 153-61. [Abstract] [Full-text]
32. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
    CMAJ, 180(11): E62-71. [Abstract] [Full-text]
33. Severe malaria in an unstable setting: clinical and laboratory correlates of cerebral malaria and severe malarial anemia and a paradigm for a simplified severity scoring.
    Eur J Clin Microbiol Infect Dis, 28(6): 661-5. [Abstract] [Full-text]
34. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.
    Blood, 113(21): 5277-86. [Abstract] [Full-text]
35. Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-{alpha} on Fanconi anemia hematopoietic stem and progenitor cells.
    Blood, 113(21): 5111-20. [Abstract] [Full-text]
36. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia.
    Blood, 113(22): 5605-8. [Abstract] [Full-text]
37. Effectiveness of a redesigned iron supplementation delivery system for pregnant women in Negros Occidental, Philippines.
    Public Health Nutr, 12(7): 932-40. [Abstract] [Full-text]

© 2004-2010 Anemia Research Today. All Rights Reserved.